-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
5 views
The company's business model leverages recurring revenue streams and strong customer retention, supporting stable long-term growth. Key risks include potential regulatory changes and execution challenges that could impact future earnings. With FDA hurdles behind it and sales momentum building, Outset's Tablo is regaining traction across hospitals and ICU settings.
